Hospitals’ data breach risk doubles just before and after M&A, research finds
The complexity of combining IT systems and increased media attention before a deal could explain hospitals’ increased vulnerability, according to the paper.
Cleveland Clinic hires first chief analytics officer
Albert Marinez, who previously held a similar role at Intermountain Health, will focus on cutting costs and using data to improve patient care.
5 takeaways from health insurers’ second-quarter earnings
UnitedHealth, CVS, Elevance and peers sidestepped the worst of medical cost growth in the quarter, but many payers face uncertainty from Medicare Advantage star ratings, GLP-1s and other pressures.
Elevance snags Moody’s exec for new CFO
Current CFO John Gallina is leaving Elevance after almost three decades in various leadership roles, including seven years as CFO.
Babylon’s take-private deal with MindMaze collapses
The digital health firm said it was exiting its core operations in the U.S. and searching for a buyer for its U.K. business.
Texas judge rules in favor of doctors in latest suit over surprise billing process
The decision is expected to increase the number of claims providers file in the independent dispute resolution process, especially for smaller amounts, according to a health lawyer.
DEA open to considering special registration for telehealth controlled substance prescriptions
The announcement comes after the agency received more than 38,000 public comments in response to a proposal that would restrict telehealth prescriptions, with “a significant majority” expressing concern.
Kaiser Permanente in the black for second quarter, after loss in 2022
CFO Kathy Lancaster said Kaiser is ready to face the second half of the year after posting a $2.1 billion profit in the second quarter.
Top paying specialties less likely to recruit women and underrepresented groups
A recruitment problem may be one source of the racial and gender compensation gap in medicine, according to a new JAMA study.
FDA approves Sage, Biogen drug for postpartum depression, but rejects wider use
The approval of Zurzuvae marks the first time the FDA has approved a pill for postpartum depression.